Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or ...

The Biden administration on Tuesday proposed that weight-loss drugs be paid for by Medicaid and Medicare, potentially making ...

Novo Nordisk said on Monday it has launched its popular obesity drug Wegovy in China, the world's second-largest ...

The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.

A dose of four Wegovy injections will cost 1,400 yuan ($194), a fraction of the drug’s U.S. price, according to the Chinese ...

Novo Nordisk faces challenges in weight-loss sector, but acquisition and strong diabetes portfolio position it for future ...

The Novo Nordisk Foundation’s assets have swelled with the success of diabetes and obesity treatments Ozempic and Wegovy, the ...

Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.

Novo Nordisk will report the topline results from the REDEFINE-1 trial of CagriSema in obese patients before the end of the ...

Novo Nordisk's Wegovy launch in China begins in Shanghai at $194 per four-injection pack, significantly cheaper than U.S.

Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or ...

All doses of Novo Nordisk's weight loss injection Wegovy and diabetes drug Ozempic are now available in the U.S., according to an update on the FDA's drug shortage database. It is a sign that Novo ...